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Two different types of TNF receptors with molecular masses of 60 kDa (p60) and 80 kDa @80) have been identified. TNF is known to cause DNA 
fragmentation in certain tumor cell lines but the role of p60 and ~80 in this action is not understood. In the present study, we examined the role 
of these receptors in TNF-induced DNA fragmentation. Treatment of U-937 cells with phorbol ester caused downregulation of both types of TNF 
receptors and this was accompanied by disappearance of the TNF-induced DNA fragmentation. The removal of phorbol ester led to two 
time-dependent events: (1) the rapid regeneration of the p80 form but not the p60 form of the TNF receptor; and (2) the reappearance of 
TNF-induced DNA fragmentation. These results suggest hat the ~80 receptor could mediate the TNF-induced DNA fragmentation. 
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1. INTRODUCTION 
Tumor necrosis factor (TNF) was originally charac- 
terized as a monokine that induces necrosis of certain 
tumors in vivo [l] and exhibits a wide variety of biolog- 
ical activities in vitro, including antiproliferative activ- 
ity against tumor cells, proliferation of human fibro- 
blast, B cells, and thymocytes, antiviral effects, and in- 
duction of various genes [2]. At the early stage of action, 
in certain cells TNF also induces DNA fragmentation, 
one of the characteristic events in apoptosis [3-51. Re- 
cently the cDNAs that encode two different TNF recep- 
tors, one with an approximate molecular mass of 
60 kDa (~60) and the other of 80 kDa (p80), have been 
isolated [6-91. While epithelial cells express primarily 
~60, myeloid cells express both p60 and p80 receptors 
[lO,l I]. Receptor-specific antibodies have been used to 
demonstrate that most TNF signals are transduced 
through the ~60 receptor [12,13]. Very little is known 
about the type of signals transduced through the ~80 
receptor [l 1,14,15]. Furthermore both receptors are in- 
dependently regulated [16,171. 
Previous studies from our laboratory and others have 
shown that PMA, a potent activator of protein kinase 
C, downregulates TNF receptors [18-201, and the re- 
moval of PMA results in TNF receptor regeneration 
[18]. However, these studies were carried out prior to 
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the identification of two types of receptors, therefore, 
the type of receptor regenerated after PMA removal is 
unclear. In the present report, we investigated the regen- 
eration of TNF receptors and the transduction of signal 
after the removal of PMA. Our results demonstrate that 
only p80 form of the TNF receptor is regenerated and 
that this receptor is involved in TNF-induced DNA 
fragmentation. 
2. MATERIALS AND METHODS 
2.1. Materials 
Bacteria-derived recombinant human TNF-a, purified to homoge- 
neity with a specific activity of 5 x lo7 units/mg, was kindly provided 
by Genentech Inc., South San Francisco, CA. Polyclonal antibodies 
against each type of soluble receptor were raised in rabbits and puri- 
fied by receptor-aflinity chromatography. 
2.2. Cell lines . I 
The human histiocytic cell line U-937 (ATCC no. CRL 1593) was 
grown in RPM1 medium supplemented with fetal calf serum (FCS) 
(10%) and gentamycin (50 &ml) (essential medium). The cells were 
seeded at a density of 1 x lo5 cells/ml in T-25 flasks (Falcon 3013, 
Beckton Dickinson Labware, Lincoln Park, NJ) containing 10 ml of 
medium and grown at 37°C in an atmosphere of 95% air and 5% CO*. 
Cell cultures were split every 3 or 4 days. 
2.3. Receptor-binding assay 
Recombinant human TNF was labeled with Na’? using the Io- 
dogen procedure as described previously [21]. The specific activity of 
labeled TNF was 30 ,&i/pg. Binding assays were performed using the 
96-well method as described [22]. Briefly, cells (0.5 x lo6 cells/well) 
were incubated in a binding buffer (RPM1 1640 supplemented with 
10% FCS) in a flexible 96-well plate (Falcon 3911) with ‘*‘I-labeled 
TNF (0.5 x 106 cpm/ml) with or without 250 nM TNF and in the 
presence or absence of 2 pg/ml of anti-p60 or anti-p80 antibody for 
1 h at 4OC in a total volume of 0.1 ml. Thereafter, cells were washed 
three times with 0.15 ml of ice-cold washing buffer (PBS containing 
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0.1% BSA). Cell-bound radioactivity was then determined by a Pack- 
ard gamma-counter (model CD 5010). The binding of TNF to p60 or 
~80 receptor was calculated by subtracting TNF specific binding in the 
absence of antibody from that in the presence of either anti-p80 or 
anti-p60 receptor antibodies. Unless otherwise stated, all results were 
determined in triplicate and expressed as mean + standard error. 
2.4. DNA fragmentation assay 
The DNA fragmentation assay was carried out by the slightly mod- 
ified methods of Elias and Berry [3]. Briefly, U-937 cells were labeled 
with tritiated-thymidine ([3H]ThdR) by incubating 2 x 10’ cells/ml in 
essential medium with 0.5 pCi/ml [-‘H]ThdR at 37°C for 16 h. Cells 
were washed free of [3H]ThdR and further incubated for 1 h at 37°C. 
Cells were then washed twice, resuspended in RPMI-1640 medium, 
and plated in the 96-well plate (4 x lO?well, total volume 200~1) with 
or without different concentrations of TNF. After incubation for 4 h 
or the indicated time, cells were lysed by the addition of 100 ~1 of 
detergent buffer (10 mM Tris-HCl, pH 8.0, containing 5 mM EDTA 
and 0.6% Triton X-100) for 5 min at room temperature. High-speed 
centrifugation was performed with microcentrifuge at 12,000 x g for 
1 min. The radioactivity in the supematant indicated fragmented 
DNA release from the cells. For the total count, the cells were lysed 
by the addition of 0.02 ml of sodium dodecyl sulfate (20%). The 
percent DNA release was calculated as follows: 
96 DNA fragmentation = 
counts in the supematant 
total cell associated counts 
x 100. 
Unless otherwise stated, all results were determined in triplicate and 
expressed as means + standard error. 
3. RESULTS 
3.1. Downmodulation of TNF receptor by PMA treat- 
ment 
We first examined the effect of PMA on TNF recep- 
tors. Human histiocytic U-937 cells were treated with 
100 nM PMA for 2 h at 37°C and then specific TNF 
control PMA treated 
Fig. 1. Downmodulation of TNF receptor by PMA. Cells (5 x 10’) 
were incubated with 100 nM PMA for 2 h at 37“C, washed, and tested 
for TNF receptors as described in section 2. 
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Fig. 2. (A) Tie course of TNF induced DNA fragmentation. 
[‘H]ThdR pre-labeled cells (4 x lO“/well) were incubated with or with- 
out 1 nM TNF for indicated times at 37”C, and then fragmented DNA 
was determined as described in section 2. (B) Dose-response of DNA 
fragmentation in control cells and cells depleted of TNF receptor. 
[‘H]ThdR pre-labeled cells (1 x 106/ml) were incubated with 100 nM 
PMA for 2 h at 37’C and washed. Then cells (4 x 1OVwell) were 
incubated with different concentrations of TNF for 4 h at 37°C and 
fragmented DNA was determined as described in section 2. 
binding was determined. The treatment almost com- 
pletely downmodulated TNF receptors (Fig. 1). 
3.2. Abrogation of TNF-induced DNA fragmentation by 
PMA treatment 
DNA fragmentation, one of the markers of pro- 
grammed cell death, was used for the bioassay of TNF. 
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PMA-pretreated 
Fig. 3. Regeneration ofTNF receptor after the removal of PMA. Cells 
(1 x 106/ml) were incubated with 100 nM PMA for 2 h at 37°C and 
washed. Then the cells were resuspended in essential medium at a 
concentration of 5 x 105/ml and incubated for another 16 h at 37°C. 
Thereafter specific TNF binding to p60 and ~80 was determined as 
described in section 2. 
TNF-induced DNA fragmentation was observed 1 h 
after TNF addition, and plateaued after 3 h (Fig. 2A). 
We could thus detect TNF biological activity earlier 
than that with other biological assays including the 
cytotoxicity assay which requires 3 days of incubation. 
To examine the effect of PMA on TNF action, cells 
were prelabeled with [3H]TdR, treated with or without 
PMA for 2 h, and incubated with different concentra- 
tions of TNF. Radioactivity released from nuclei was 
measured in the supernatant. In a dose-dependent man- 
ner, TNF induced DNA fragmentation in untreated 
U-937 cells, and the fragmentation reached its maxi- 
mum at 1 nM TNF. Under these conditions, no TNF- 
induced DNA fragmentation in PMA-treated cells was 
detected (Fig. 2B). 
3.3. Regeneration of the p80 form of TNF receptor after 
the removal of PMA 
We previously reported that TNF receptor is regener- 
ated after removal of PMA [18] but the type of receptor 
regenerated is not known. In order to investigate this, 
U-937 cells were treated with 100 nM PMA for 2 h, 
washed, incubated for an additional 16 h at 37°C and 
examined for the specific TNF binding. Anti-p60 and 
anti-p80 antibodies were added during the binding ex- 
periment to distinguish between p60- and p80-specific 
binding. As we reported before [23], the p60 and ~80 
receptor contributed 30% and 85%, respectively, of the 
total binding on untreated U-937 cells (Fig. 3). However 
on cells pretreated with PMA, p80 receptor contributed 
almost entirely all of the specific TNF binding, indicat- 
ing that only the p80 receptor was regenerated (Fig. 3). 
3.4. Recovery of TNF-induced DNA fragmentation after 
PA4A removal 
We next examined the TNF-induced DNA fragmen- 
tation in cells which express only p80 receptor after 
regeneration. TNF caused the DNA fragmentation in 
both control untreated cells which express p60 and p80 
receptor and in PMA pretreated cells which express 
only p80 receptor (Fig. 4). However, in the latter higher 
concentration of TNF was needed for DNA fragmenta- 
tion. These results suggest that the p80 receptor can 
transduce the TNF signal on U-937 cells. 
4. DISCUSSION 
In the present report, we demonstrate that both TNF 
receptors are completely downregulated by PMA treat- 
ment and that after the removal of PMA, p80 but not 
p60 receptor is regenerated. Why only the p80 receptor 
and not the p60 receptor was regenerated after the re- 
moval of PMA is not clear. However, this result is con- 
TNF [PM] 
Fig. 4. Recovery of the effect of TNF-induced DNA fragmentation 
after the removal of PMA. [‘H]ThdR pre-labeled cells (1 x lo6 cells/ 
ml) were incubated with 100 nM PMA for 2 h at 37’C and washed. 
For receptor regeneration, the cells were resuspended in essential 
medium at the concentration of 5 x 10’ cells/ml and incubated for 
another 16 h at 37°C. Cells were washed, and incubated (4 x 10%) 
with or without different concentrations of TNF for 4 h at 37°C. 
Fragmented DNA was then determined as described in section 2. 
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sistent with our previous report indicating that PMA 
selectively induces the mRNA for only p80 receptor 
[24]. Experiments with the promoter region of the mur- 
ine p60 receptor gene also indicate that it does not re- 
spond to a variety of stimuli [25]. TNF-induced DNA 
fragmentation, used to detect the biological action of 
TNF, disappeared after PMA treatment in the cells 
which express no TNF receptor, but was recovered after 
the removal of PMA in the cells which express only p80 
receptor, indicating that p80 receptor transduces this 
TNF signal. However, in the presence of PMA for a 
longer period of time, p80 was regenerated but no DNA 
fragmentation was evident (data not shown). From 
these observations, we conclude that PMA inhibits 
TNF action through two mechanisms; downregulation 
of the TNF receptor and inhibition of post-receptor 
signalling. 
By using agonistic and antagonistic antibodies, it has 
been demonstrated that p60 receptor transduces most 
TNF signals including cytotoxicity, growth stimulation, 
differentiation and DNA fragmentation [3-5,12,13,17]. 
However, only very few signals have been reported to 
be mediated through the p80 receptor and this includes 
the activation of NF-kB, cytotoxicity, and stimulation 
of growth [I 1,14,15]. Since two types of TNF receptors 
can cross-modulate ach other [23], therefore, the type 
of signal transduced by the individual receptor is not 
clear. No cell line has so far been described which ex- 
presses exclusively one type of TNF receptor. Our re- 
port clearly demonstrates that TNF can cause DNA 
fragmentation in the absence of any detectable p60 re- 
ceptor. The concentration of TNF needed for DNA 
fragmentation in cells expressing only p80 receptor was 
found to be higher than that which express both types 
of TNF receptors. This difference may be either due to 
the affinity of TNF to p80 receptor or may also suggest 
the role of p60 receptor. Furthermore, we could not 
detect TNF-induced DNA fragmentation in epithelial 
cells which express primarily p60 receptor (data not 
shown), therefore, also suggesting the role of p80 recep- 
tor for the TNF-induced DNA fragmentation. Thus, in 
conclusion, our results demonstrate a selective resyn- 
thesis of p80 form of the TNF receptor in cells pre- 
treated with phorbol ester and also document the role 
of this receptor in DNA fragmentation. 
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